Skip to main content
Connect with one of our Dutch experts
Get in touch
Osborne Clarke
en
en en
  • en en
  • nl nl
  • fr fr
  • de de
  • it it
  • es es
  • sv sv
  • pl pl
Search Close

Search results

  • Back
  • People
  • Expertise
    • Back
    • Transformation
      • Back
      • Decarbonisation
      • Digitalisation
      • Urban Dynamics
      • Data-driven business models: the role of legal teams in delivering success
    • Sectors
      • Back
      • Energy and Utilities
      • Financial Services
      • Life Sciences and Healthcare
      • Mobility and Infrastructure
      • Real Estate and Infrastructure
      • Retail and Consumer
      • Tech, Media and Comms
      • Workforce Solutions
      • All sectors
    • Services
      • Back
      • Banking and finance
      • Commercial
      • Competition, antitrust and trade
      • Corporate
      • Dispute resolution
      • Employment and pensions
      • ESG – Environmental, Social and Governance
      • Infrastructure services
      • Intellectual property
      • IT and data
      • Public law
      • Real estate
      • Regulatory and compliance
      • Tax
      • All Services
  • Osborne Clarke Solutions
  • Insights
    • Back
    • Headlines
    • Transformation
      • Back
      • Decarbonisation
      • Digitalisation
      • Urban Dynamics
    • Insights: sector
      • Back
      • Energy and Utilities
      • Financial services
      • Life Sciences and Healthcare
      • Real Estate and Infrastructure
      • Retail and Consumer
      • Tech, Media and Comms
      • Mobility and Infrastructure
      • Workforce Solutions
    • Insights: service
      • Back
      • Banking and finance
      • Commercial
      • Competition, antitrust and trade
      • Corporate
      • Dispute resolution
      • Employment and pensions
      • Infrastructure services
      • Intellectual property
      • IT and Data
      • Real Estate
      • Regulatory and Compliance
      • Tax
    • Key topics
      • Back
      • Blockchain
      • Brexit
      • ESG, Sustainability and Responsible Business
      • Elektromobilität
      • European Electronic Communication Code
      • GDPR
      • Global Compliance
      • Knowledge Notes
      • Managing Covid-19
      • Online Safety
      • Regulatory Outlook
      • Sanctions, ownership and related issues
      • Supply chains
      • Sustainable disruption: 12 decarbonising technologies for cities
      • The metaverse
      • The New Deal for Consumers
    • Events
    • All insights
  • Locations
    • Back
    • Belgium
    • China
    • France
    • Germany
    • India
    • Italy
    • The Netherlands
    • Poland
    • Singapore
    • Spain
    • Sweden
    • UK
    • US
    • View all locations
  • Careers
    • Back
    • Careers in Belgium
    • Careers in France
    • Careers in Germany
    • Careers in Italy
    • Careers in Poland
    • Careers in Spain
    • Careers in Sweden
    • Careers in the Netherlands
    • Careers in the UK
    • Careers in the US
    • View all careers
  • About us
    • Back
    • Helping you succeed in tomorrow's world
    • News
    • Osborne Clarke For Good
Close
Around the world
  • Belgium
  • China
  • France
  • Germany
  • India
  • Italy
  • The Netherlands
  • Poland
  • Singapore
  • Spain
  • Sweden
  • UK
  • US
View All Locations
Share

Osborne Clarke Health Check - Spring 2023 Webinar Series

A series on leveraging regulations to maximise opportunities in the Life Sciences and Healthcare industry

Breadcrumb

  • Home
  • Osborne Clarke Health Check - Spring 2023 Webinar Series

Significant change is coming that will affect how life sciences and healthcare products and services are brought to the market. Patient and consumer expectations are ever higher, the UK government has begun to detail how Brexit will affect the sector and the fallout from the pandemic is influencing how healthcare services are regulated. 

Osborne Clarke's Life Sciences and Healthcare regulatory team is delighted to invite you to our Spring 2023 webinar series, focussed on unpicking key regulatory and legal developments to help companies commercialise new products and services. 

We hope you'll be able to join us. 

Register here

Strategies to reduce the liability and regulatory risks that affect innovative products

Innovative products come with a heightened risk of attracting product liability litigation and regulatory investigations. As the EU Medical Device Regulation enters its second year of application, and the UK gears up for its own new regulations, manufacturers need to adapt their strategies to mitigate their risks.

In this webinar Peter Rudd-Clarke, Anna Lundy and Stefanie Lo covered: learning lessons from recent high profile life sciences litigation; capitalising on new laws and regulations to launch innovative products whilst reducing legal risks; and negotiating with your supply chain to allocate liability and regulatory risks.

View the webinar recording here

The future of healthcare regulation in the UK: what you need to know

14 March 2023 | 09:30 - 10:30 GMT

With the NHS in crisis and a transformation in the Care Quality Commission's (CQC's) regulatory approach, major changes are coming to the way that the safety and quality of health and social care is regulated. Reshma Adkin and Alice Babington will share their tips on how this will affect businesses in 2023.

View the webinar recording here

The personalisation of life sciences products

3 May 2023 | 09:30 - 10:30 BST

We are anticipating developments in legislation before the date of this webinar, so further detail on the exact content will be finalised nearer the time.

Register

Connect with one of our experts

Peter Rudd-Clarke
Partner, UK
+44 207 105 7315 Email Peter Full biog
Anna Lundy
Associate Director, UK
+44 207 105 7075 Email Anna Full biog
Reshma Adkin
Associate Director, UK
+44 117 917 3334 Email Reshma Full biog
Stefanie Lo
Associate, UK
+44 207 105 7649 Email Stefanie Full biog
Alice Babington
Associate, UK
+ 44 117 917 3918 Email Alice Full biog

Resources

Life Sciences and Healthcare
Products without an intended medical purpose: EU clarifies conditions
20/12/2022
Life Sciences and Healthcare
Regulatory Horizons Council makes recommendations to UK government for the regulation of AI as a medical device
'Urgent need to get the regulation right' says RHC report which recommends an increase in regulatory capacity and capability to...
12/12/2022
Life Sciences and Healthcare
UK lays out roadmap for regulation of software and AI as medical devices
What 'deliverables' does the MHRA want from its roadmap and what can be expected from its work packages?
28/10/2022
Life Sciences and Healthcare
MHRA moves to assuage medical device manufacturers over UK's post-Brexit plans
Businesses will have more time to prepare for the new UKCA marking regime and comment on draft medical device regulations
26/10/2022
Life Sciences and Healthcare
Zantac clash is reminder for life sciences industry of need for litigation strategies
Robust defences are critical when litigation concerns one product but multiple claimants and jurisdictions
26/08/2022
Life Sciences and Healthcare
Updated CQC guidance has implications for the health technology and wellbeing industries
Reworked guidance reflects the evolution in models for healthcare service delivery, especially with regard to technological innovation
08/07/2022
View all insights

Explore

  • People
  • Sectors
  • Transformation
  • Services
  • Insights
  • Events
  • Locations

Useful links

  • Site map
  • Terms and conditions
  • Contact us
  • Privacy policy
  • California Privacy Notice
  • Slavery statement
  • Alumni
  • Cookie policy
  • Transparency

Sign up for our newsletter

Register now for more insights, news and events from across Osborne Clarke.
Sign up

Follow us

Osborne Clarke
Legal Notice
When you read about Osborne Clarke on this site, we are either referring to our international organisation, Osborne Clarke Verein (OCV), or one of its member firms. OCV is a Swiss verein and doesn’t provide services to clients. The OCV member firms are all separate legal entities and have no authority to obligate or bind each other or OCV with regard to third parties. To find out more, please click here.